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Abstract
Background: Congenital muscular dystrophy type 1A (MDC1A), also termed 
merosin-deficient congenital muscular dystrophy (CMD), is a severe form of CMD 
caused by mutations in the laminin α2 gene (LAMA2). Of the more than 300 likely 
pathogenic variants found in the Leiden Open Variant Database, the majority are 
truncating mutations leading to complete LAMA2 loss of function, but multiple copy 
number variants (CNVs) have also been reported with variable frequency.
Methods: We collected a cohort of individuals diagnosed with likely MDC1A and 
sought to identify both single nucleotide variants and small and larger CNVs via 
exome sequencing by extending the analysis of sequencing data to detect splicing 
changes and CNVs.
Results: Standard exome analysis identified multiple novel LAMA2 variants in our 
cohort, but only four cases carried biallelic variants. Since likely truncating LAMA2 
variants are often found in heterozygosity without a second allele, we performed ad-
ditional splicing and CNV analysis on exome data and identified one splice change 
outside of the canonical sequences and three CNVs, in the remaining four cases.
Conclusions: Our findings support the expectation that a portion of MDC1A cases 
may be caused by at least one CNV allele and show how these changes can be ef-
fectively identified by additional analysis of existing exome data.
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1 |  INTRODUCTION
Congenital muscular dystrophies (CMDs) are neuromuscu-
lar disorders presenting as muscle weakness from birth or 
early infancy that are usually associated with severe muscu-
lar dystrophy (MD) and variable brain malformations (Kang 
et al., 2015; O'Grady et al., 2016). Among CMDs, congenital 
muscular dystrophy type 1A (MDC1A) [MIM: 607855], also 
termed merosin-deficient CMD, has a characteristic presen-
tation with congenital or early-onset MD and often changes 
in the white matter in the brain (Bönnemann et  al.,  2014; 
Geranmayeh et  al., 2010). MDC1A is caused by mutations 
in laminin α2 gene (LAMA2) [MIM:156225] a component of 
the Laminin-211 heterotrimer (Helbling-Leclerc et al., 1995).
Multiple studies on genotype/phenotype correlation of 
LAMA2 mutations have shown that severe MDC1A is usually 
associated with truncating mutations and deletions leading 
to total loss of protein (Geranmayeh et  al.,  2010; Oliveira 
et  al.,  2008, 2018; Pegoraro et  al.,  1998). While previous 
studies of large patient cohorts have been able to identify 
all disease mutations in roughly 80% of cases, recent ef-
forts using whole exome sequencing (WES) and copy num-
ber variant (CNV) analysis, have shown that approximately 
95% of disease mutations can be identified, leaving about 
5% of patients with only one identified heterozygous variant 
(Oliveira et al., 2018).
According to the Leiden Open Variant Database (LOVD), 
there are over 300 unique variants in LAMA2 which are dis-
ease causing (Oliveira et al., 2018). Of these variants, around 
half (54%) are protein-truncating variants (nonsense or 
frameshift inducing small deletions or insertions) and 25.6% 
are predicted to affect splicing. Missense SNVs account for 
a smaller percentage (12.9%) of individuals and tend to fall 
within specific protein domains in the N-terminal domain and 
the C-terminal G-like domains. The final group of disease 
associated variants consists of large duplications and dele-
tions, also known as copy number variants (CNVs). There are 
21 unique CNVs reported thus far (6.8%) which are mostly 
deletions (17/21). The rate of CNVs in LOVD may not be 
representative of the population, however, as past studies of 
large patient cohorts has yielded approximately 18% of dis-
ease-causing variants as CNVs (Oliveira et al., 2014; Xiong 
et al., 2015).
In the present study, we combine standard exome variant 
analysis with splicing change analysis and CNV prediction 
identifying likely causative biallelic variants in seven out of 
eight individuals. We expand the known list of pathogenic 
genetic variants in LAMA2 that cause CMD by adding three 
previously unpublished single nucleotide changes. In ad-
dition, we report a novel large duplication of exons 6–12. 
Overall, our study supports the hypothesis that CNVs are un-
derdiagnosed in MDC1A and that combination of WES and 
CNV analysis can be beneficial in the genetic diagnosis of 
this disorder.
2 |  METHODS
2.1 | Ethical compliance
This study was performed with approval from the Institutional 
Review Boards of the George Washington University, 
Rutgers University, the Children's National Health System, 
the Hope Generation Genetic Clinic, and the Fondazione 
IRCCS Istituto Neurologico Carlo Besta.
2.2 | Study participants
All study participants presented with severe CMD at birth or 
within the first 2 years of age. Muscle biopsies for patients 
(P)1–2 and P5–8 were performed for diagnostic purposes at 
Children's National Medical Center in Washington DC show-
ing loss of merosin and were banked by the Hoffman labora-
tory. P3 was enrolled at the Hope Generation Genetic Clinic 
in Iran with a presentation consistent with MDC1A and P4 
was enrolled at the Fondazione IRCCS Istituto Neurologico 
Carlo Besta in Milan, Italy following a diagnosis of CMD 
and loss of merosin upon biopsy.
2.3 | Muscle biopsy histological analysis
Muscle biopsies were flash frozen and cryosectioned for his-
tological examination and immunohistochemistry. Samples 
were stained with hematoxylin and eosin (H&E) and read 
by an expert muscle pathologist to identify signs of MD and 
the level of muscle disease severity. A C-terminal laminin 
α2 antibody (MAB1922, Millipore Sigma) was used to test 
for merosin expression. P4 did not receive a muscle biopsy.
2.4 | Whole exome sequencing analysis
DNA was extracted from the subject's muscle (P1–2, 5–8) 
or blood (P3, 4). Whole exome sequencing was performed 
K E Y W O R D S
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at the Broad Institute Genomic Services (Broad Institute, 
Cambridge, MA) through their Germline Exome pipeline. 
Sequencing reads were aligned to reference genome hg19 
using Burrows Wheeler Aligner (Li & Durbin,  2010). The 
Genome Analysis Toolkit was used to call variants using 
the best practices protocol for variant analysis (McKenna 
et  al.,  2010; Van der Auwera et  al.,  2013). Variants were 
annotated using Annovar (Wang, Li, & Hakonarson, 2010), 
loaded into an SQL database, and filtered with custom que-
ries to identify rare, homozygous, and compound heterozy-
gous nonsynonymous mutations. Variants were filtered 
for frequency lower than 1% in the Genome Aggregation 
Database (gnomAD; Lek et  al.,  2016) and for coding 
changes resulting in missense, truncating, splicing changes, 
or small deletions and duplications. Candidate variants 
were then examined for frequency in the sequencing reads 
to remove sequencing errors using Integrative Genomics 
Viewer (Robinson et  al.,  2011). Previously reported clini-
cal information for each variant was gathered from Clinvar 
(Landrum et  al.,  2018), Leiden Open Variation Database 
(Fokkema, 2011), and the Human Gene Mutation Database 
(Stenson et al., 2017). Variants were scored according to the 
guidelines from the American College of Medical Genetics 
and Genomics (Richards et al., 2015) using InterVar (Li & 
Wang, 2017).
2.5 | Bioinformatic analysis of missense and 
splicing LAMA2 variants
All candidate missense and splicing variants in LAMA2 
were analyzed for predicted effect on protein function and 
splicing where applicable. SIFT and Polyphen2 were used 
for pathogenicity prediction for missense variants as part of 
the variant annotation with Annovar (Adzhubei et al., 2010; 
Sim et  al.,  2012). CADD (v1.4) was used as an additional 
pathogenicity prediction tool using the CADD web resource 
(Rentzsch, Witten, Cooper, Shendure, & Kircher,  2019). 
The online server for Human Splicing Finder (HSF, ver-
sion 3.1), and NNSplice was used to predict possible effects 
on splicing (Desmet et al., 2009; Reese, Eeckman, Kulp, & 
Haussler, 1997). All variants were tested in HSF for possible 
splicing enhancers and silencers. Only variants that were less 
than four bases into the exon or less than 21 bases into the 
intron were run through NNSplice, as this tool only evaluates 
the original donor and acceptor sites. Scores for NNSplice 
are from the maximum entropy model (Yeo & Burge, 2004).
2.6 | Copy number variant (CNV) 
analysis and multiplex ligation-dependent 
probe amplification (MLPA) validation
All samples were interrogated for CNVs. Normalized cover-
age profiles were analyzed for copy number variation using 
ExomeDepth as described (Plagnol et  al.,  2012) and using 
recommended parameters. CNV calls were annotated against 
common CNVs (Conrad et  al.,  2010). MLPA was used to 
validate in silico CNV analysis using the SALSA MLPA 
P391 LAMA2 mix 1 probemix version 2 (MRC-Holland). 
FAM-labeled PCR products were generated using approxi-
mately 200 ng of genomic DNA and analyzed as outlined in 
the MLPA general protocol (MRC-Holland). PCR products 
were quantified via capillary electrophoresis using an ABI 
T A B L E  1  Muscle biopsy report and clinical findings in the study cohort
Pat
Muscle biopsy Immunohistochemistry
Other motor findings Brain imagingDystrophic DYS LAMA2 SCGA DYSF
P1 Yes, severe + − + + n/a n/a
P2 Yes, severe + − + + n/a n/a
P3 n/a n/a n/a n/a n/a Hypotonia MRI: Cerebral atrophy, 
leukodystrophy, posterior 
lissencephaly
P4 Yes, severe + − n/a n/a Hypotonia MRI: Diffuse white matter 
changes
P5 Yes, severe + Partial Partial n/a Congenital weakness, high 
CK
CT:normal
P6 Yes, severe n/a − n/a n/a Hypotonia, decreased deep 
tendon reflexes
n/a
P7 Yes, severe n/a − n/a n/a Hypotonia n/a
P8 Yes, severe + − + + n/a n/a
Abbreviations: −, absent; +, present; DYS, dystrophin; DYSF, dysferlin; LAMA2, laminin α2; n/a, not available; Pat, patient; SCGA, α-sarcoglycan.
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3500 Genetic Analyzer (Applied Biosystems) by adding 1 µL 
PCR product to a mixture of 9.75 µL Hi-Di™ Formamide and 
0.25 µL GeneScan™ 500 LIZ™ dye Size Standard (Thermo 
Fisher). Peak intensities were analyzed using the Coffalyser 
software (MRC-Holland) to detect deviations from the stand-
ard DNA copy number of 12 reference samples and one neg-
ative control.
3 |  RESULTS
3.1 | Study cohort
All study participants were referred to a neuromuscular clinic 
before 2 years of age presenting with hypotonia and likely 
muscle disease, but additional clinical information was frag-
mentary (Table  1). Muscle biopsy information was avail-
able for all patients for H&E staining showing muscle fiber 
replacement with changes in fiber size, fibrosis, variable 
presentation of fat infiltration, and inflammation, leading 
to a congenital muscular dystrophy diagnosis by a patholo-
gist. Brain imaging information was also available for three 
cases in the form of either computerized tomography (CT) 
scan (P5) or magnetic resonance imaging (MRI) (P3, 4). P5 
showed normal brain imaging. P3 was reported to have cer-
ebral atrophy, which was more severe frontally, white matter 
changes, and posterior lissencephaly and severe developmen-
tal delay. P4 showed diffuse white matter alteration, but no 
cognitive impairment was present.
3.2 | Identification of pathogenic single 
nucleotide variants in LAMA2
Initial exome sequencing analysis filtered for rare protein-
altering variants (<1% frequency in gnomAD) in known 
CMD genes. Likely pathogenic variants in LAMA2 were 
identified in seven individuals, leading to the identification 
of three novel variants (Table 2, Figure 1). However, only 
four out of eight patients had biallelic LAMA2 changes. 
Protein-truncating mutations were found in three indi-
viduals. All variants reported below were mapped on tran-
script NM_000426.3 and protein NP_000417.2. In P1 we 
found a novel heterozygous one base pair (bp) deletion 
c.8038delG, p.(Gly2682Alafs*46), in exon 57, in combina-
tion with a heterozygous nonsense variant which was previ-
ously reported to be pathogenic c.5476C>T, p.(Arg1826*) 
(Naom et al., 1998). P2 had a homozygous splicing variant 
T A B L E  2  Genetic variants identified in the study cohort
Patient Analysis
DNA change
NM_000426.3
Genomic location
hg19 Exon
Protein change
NP_000417.2 Interpretation Publication
P1 1 het c.5476C>T chr6:129722399 38 p.(Arg1826*) Pathogenic Naom 
et al. (1998)
1 het c.8038delG chr6:129813191 56 p.(Gly2682fs*46) Pathogenic Novel
P2 1 hom c.396+1G> T chr6:129381042 Int 3 Splicing Pathogenic Oliveira 
et al. (2018)
P3 1 hom c.2540G>T chr6:129608994 19 p.(Cys847Phe) VUS Novel
P4 1 hom c.3085C>T chr6:129621928 22 p.(Arg1029*) Pathogenic Allamand & 
Guicheney 
(2002)
P5 1 het c.2230C>T chr6:12588272 16 p.(Arg744*) Pathogenic Di Blasi (2001)
1 het c.4960-17C>A chr6:129704250 Int 34 Splicing VUS Oliveira 
et al. (2018)
P6 1 het 
c.4710_4711delGT
chr6:129674495-
129674496
32 p.(Cys1571fs*5) Pathogenic Novel
2 het c.820_1782dup chr6:129468105-
129513998
6–12 p.(274_594)dup Likely 
pathogenic
Novel
P7 1 het c.6955C>T chr6:129781432 49 p.(Arg2319*) Pathogenic Pegoraro 
et al. (1998)
2 het c.7893_8069del chr6:129807620-
129807767
56 p.(Ala2584Hisfs*8) Pathogenic Oliveira 
et al. (2008)
P8 2 het c.397_639del chr6:129419319-
129419560
4 p.(133–213)del Likely 
pathogenic
Xiong 
et al. (2015)
? ? ? ? ?
Abbreviations: het, heterozygous; hom, homozygous; int, intron; VUS, variant of uncertain significance.
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c.396+1G>T altering the canonical splice site and pre-
viously reported in several MDC1A patients as both a 
homozygous and compound heterozygous pathogenic mu-
tation (Oliveira et  al.,  2018). P4 had a homozygous non-
sense variant c.3085C>T, p.(Arg1029*), which also had 
been previously reported(Allamand & Guicheney,  2002; 
Oliveira et  al.,  2008). P3 had a novel homozygous mis-
sense variant c.2540G>T (p.Cys847Phe). Pathogenicity 
prediction tools consistently indicated the variant likely 
has a profound impact on protein function: SIFT (0.000), 
PolyPhen (1.000), and CADD (32.0).
Three individuals showed only one likely deleterious al-
lele. P5 had a heterozygous nonsense mutation c.2230C>T 
(p.Arg744*) that was previously reported to create an in 
frame skipping of exon 15 and a truncated protein product 
in a case of mild MDC1A (Di Blasi, 2001). P6 had a novel 
heterozygous 2bp deletion c.4710_4711delGT leading to a 
frameshift (p.Val1572Phefs*5). P7 had a heterozygous vari-
ant c.6955C>T (p.Arg2319*) and had been previously se-
quenced for LAMA2 by Pegoraro et al. who reported only this 
variant and were not able to identify a second one (Pegoraro 
et al., 1998).
Additional analysis of the intronic regions captured by 
exome sequencing did not identify any candidate variants for 
P6 and P7, but showed a second heterozygous intronic variant 
(c.4960-17C>A) in P5 (Table 2). This variant had been pre-
viously reported by Oliveira et al. (2018), but had never been 
evaluated for its possible effect on splicing. We performed 
splicing prediction analysis on this variant and included the 
missense variant in P3 using the canonical splice variant in 
P2 as a positive control. Since splicing prediction is based 
on probabilistic approaches, we used a combination of algo-
rithms using different models which analyze the surrounding 
sequence to determine whether a variant is likely to generate 
a strong new splice donor or acceptor (Table 3). Whenever 
applicable, we tested the variants with Human Splicing 
Finder (HSF) which combines multiple prediction models 
and prediction of splicing branch point (Desmet et al., 2009), 
and NNSplice which is based on a machine learning ap-
proach where a neural network is trained to detect splicing 
events (Reese et al., 1997). As expected the canonical splice 
variant in P2 was predicted to break the splice donor. Both 
splicing evaluation tools predicted that the c.4960-17C>A 
variant in P5 would change the acceptor site in intron 34, 
F I G U R E  1  Schematic representation of protein variant, splicing changes, and CNVs identified in LAMA2. Protein changes generated by 
single nucleotide variants (SNVs) and small deletions and duplications (InDels) are shown above the protein schematic. Location of splicing 
changes is indicated by labels starting with “c.” showing the corresponding location in the coding sequence. Copy number variants (CNVs) are 
shown below the protein as black boxes. Domain abbreviations are as follows: LN, Laminin N-terminal; LE, Laminin-type-EGF-like; LG, Laminin-
type G. Two globular L4 domains are also shown in light blue and coiled-coil domain in purple. Protein sequence: GenBank NP_000417.2
T A B L E  3  Bioinformatic analysis of missense and splicing mutations
Pat DNA Variant
Protein 
variant Nearest junction
Pathogenicity prediction Splicing prediction
SIFT Polyphen2 CADD HSF
NNSplice
Ref->Mut (alt)
P2 c.396+1G>T Intronic +1 bp,
Intron 3 donor
— — — ++ broken 
donor site
0.71 ->0.00
P5 c.4960-17C>A Intronic −17 bp,
Intron 34 acceptor
— — — + new acceptor 
site
0 ->0.72
P3 c.2540G>T p.(Cys847Phe) +3 bp,
Intron 18 acceptor
0.000 1.000 32.0 + new ESS 0.93 ->0.94
Note: DNA and Protein GenBank Accession: NM_000426.3, NP_000417.2.
Abbreviations: +, potentially affects splicing; 1, probably damaging; 1, tolerated; 10, top 1%; 20, top 0.1%; bp, base pairs; CADD: phred scores; ESE, exonic splicing 
enhancer; ESS, exonic splicing silencer; HSF: ++, Most probable to effect splicing; Nearest Junction: junction, exon/intron boundary; NNSplice: alt, alternative donor 
or acceptor site. Score 0 > 1; Pat, patient; Polyphen2: 0, benign; SIFT: 0, deleterious.
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with HSF predicting the loss of the canonical site, and both 
HSF and NNSplice predicting the creation of a new acceptor 
at the variant location instead. Additional experimental con-
firmation is still needed to determine how mRNA splicing is 
disrupted.
The homozygous missense variant in P3 (c.2540G>T) is 
located in exon 19 3bp downstream from the splice acceptor 
of intron 18 and HSF and NNSplice indicated limited impact 
on splicing and considering the high scores in pathogenicity 
prediction algorithms, these additional findings support the 
hypothesis that this is a deleterious missense variants with no 
effect on splicing (Table 3).
3.3 | Copy number variant identification 
in LAMA2
We then analyzed this cohort using ExomeDepth, an in silico 
CNV analysis approach to identify large duplications and de-
letions in exome sequencing. We tested all exomes in our 
cohort to determine how CNVs contribute to the mutation 
burden in this group and identified three CNVs, two dele-
tions and one duplication (Table  2, Figure  1). We discov-
ered a large heterozygous duplication of exon 6 through 12 
as the second allele in P6 c.820_1782dup, (p.274_594dup). 
While the duplication is in frame, it covers sections of both 
the N-terminal domain as well as a Laminin-type-EGF-like 
domain, which are both critical to the formation of basement 
membrane structure through self-polymerization of laminin. 
Of note, there was a previously reported large duplication of 
exons 5–12 in a patient with an LGMD/Becker muscular dys-
trophy-like phenotype where no second mutation was found 
(Piluso et al., 2011). We also found a second allele in P7: a 
heterozygous deletion of exon 56, c.7750_7899del, predicted 
to cause a truncating frameshift (p.Ala2584Hisfs*8), which is 
likely the same as a CNV found frequently in the Portuguese 
population (Oliveira et al., 2008). From break point analysis 
in previous studies, the frequently reported exon 56 deletion 
also includes deletion of large portions of the flanking introns 
(Oliveira et al., 2014).
Finally, a heterozygous large deletion of exon 4, 
c.397_639del, (p.133_213del) previously reported as a 
pathogenic CNV and a founder mutation in the Han Chinese 
population (Ge et al., 2018; Xiong et al., 2015) was identified 
in P8. Patients with homozygous deletions of exon 4 exhib-
ited the typical signs of MDC1A with loss of muscle laminin 
α2, CMD, and white matter changes (Xiong et al., 2015). No 
second variant was discovered in this individual.
Multiplex Ligation-dependent Probe Amplification 
(MLPA) Validation was performed to confirm these CNVs 
(Figure 2) in these cases and in a group of control samples, 
including normal skeletal muscle and P1, 2, and 5. CNVs 
were confirmed as a 50% loss of DNA in P7 and P8 and as 
a 50% increase in P6, indicating that CNV prediction was 
accurate and can be used to identify large deletions and du-
plications from exome sequencing data.
4 |  DISCUSSION
Here, we present a cohort of MDC1A patients carrying both 
novel and known single nucleotide variants and CNVs. Due 
to the high frequency of CNVs among LAMA2 mutations, 
only one likely pathogenic variant is identified via DNA se-
quencing in some cases (Geranmayeh et al., 2010; Oliveira 
et al., 2018; Pegoraro et al., 1998). In fact, only 50% of our 
cases showed biallelic changes in LAMA2 through exome se-
quencing and only when additional scrutiny was extended to 
the intronic regions. By combining variant filtering for rare 
SNPs and small indels with CNV analysis, we were able to 
F I G U R E  2  Multiplex Ligation-dependent Probe Amplification (MLPA) confirms CNVs predicted via exome analysis. CNVs predicted in P6, 
P7, and P8 were tested using MLPA probes for a subset of LAMA2 exons, in parallel to five control sample, two normal skeletal muscle samples 
and three cases from this study (P1, P2 and P5). A heterozygous duplication spanning from exon 6 to exon 12 was confirmed in P6 (red squares), as 
were single exon deletions in P7 (blue diamonds) and P8 (green triangles)
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identify two alleles in most individuals and an additional 
heterozygous deletion in one patient (Table  2, Figure  1). 
The majority of identified variants (8/12) resulted in a pro-
tein truncation via a nonsense (n = 4), splicing (n = 2), or a 
frameshift change due to a small deletion (n = 2). Of these 
variants, two were unpublished, while the remaining were 
previously published as pathogenic either in homozygosity 
or compound heterozygosity with other variants. In all these 
cases, complete or partial loss of laminin α2 was identified by 
immunohistochemistry (Table 1).
One patients had a novel missense variant. The laminin α2 
protein is composed of three major protein regions including a 
globular laminin N-terminal domain (LN), multiple Laminin-
type-EGF-like (LE) domains at the N-terminus, a central 
coiled-coil domain, and five laminin-type G (LG) globular 
domains at the C-terminus (Hohenester & Yurchenco, 2013). 
Hotspots for missense mutations in LAMA2 are located in 
the LN and in the three LE domains likely disrupting as-
sembly of the basement membrane and in the LG domains 
affecting binding to membrane proteins (Figure 1) (Oliveira 
et al., 2018). The homozygous change p.(Cys847Phe) in P3, 
which was predicted to be pathogenic by multiple algorithms, 
would affect one of LE domains (LEb, Figure 1) which binds 
to other components of the extra-cellular matrix (ECM) or-
ganizing and stabilizing the basement membrane (McKee, 
Harrison, Capizzi, & Yurchenco, 2007).
Additional analysis for CNVs proved effective in identify-
ing two large deletions and a large duplication and providing 
genetic information for an additional three cases. The novel 
exon 6–12 duplication (p.274_594dup), while in frame, af-
fects part of LN and the entire LEa domain. Similarly, the in 
frame deletion in exon 4 (p.133_213del) would remove part 
of LN. The heterozygous deletion in exon 56 would instead 
cause a frameshift at the C-terminus of the protein starting 
from the third LG domain (Figure 1).
In addition to identifying novel variants in LAMA2, our 
study provides further information on the biological impor-
tance of previously published variants which were reported 
without characterization. We also show that analysis of 
next-generation sequencing data for CNVs can be a rapid and 
cost-effective method for identifying additional variants in 
cases where only one heterozygous likely pathogenic change 
is found. Provided sufficient coverage of at least 30 reads per 
exon (Plagnol et al., 2012), this approach could be effective 
to inexpensively identify additional alleles in existing exome 
data and has been validated in multiple large disease cohorts 
(Ellingford et al., 2017; Marchuk et al., 2018). Overall, our 
findings show how CNV analysis can further leverage exome 
data to provide a genetic diagnosis for CMD cases.
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